ACTRN12615001169538终止1 期
A Phase Ib study of lenalidomide in combination with imatinib for adult patients with chronic myeloid leukaemia in second molecular remission
South Australian Health & Medical Research Institute (SAHMRI)0 个研究点目标入组 3 人开始时间: 2015年11月2日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Diagnosis of chronic myeloid leukaemia associated with BCR-ABL quantifiable by RQ-PCR at the time of commencing imatinib therapy.
- •2. Patient experienced molecular recurrence of BCR-ABL during a previous medically supervised period of imatinib withdrawal, resulting in resumption of imatinib treatment, and:
- •a. MR4.5 at the time of having previously stopped imatinib.
- •b. No more than two BCR-ABL results above 0.01% in the two year period prior to having stopped imatinib.
- •c. Willing and able to provide all BCR-ABL RQ-PCR results from the two year period prior to having stopped imatinib, and for the period up to the time of restarting imatinib treatment.
- •3. Patient regained MR4.5 after restarting imatinib treatment (as detailed in criterion 3) and has maintained MR4.5 on at least 2 tests in the 12 months prior to screening, and:
- •a. No BCR-ABL result above 0.1% (MMR) in the 12 month period prior to screening.
- •b. No more than one BCR-ABL result above 0.01% in the 12 month period prior to screening.
- •c. Willing and able to provide copies of all BCR-ABL RQ-PCR test results from the 12 month period prior to screening.
- •4. Currently taking imatinib and no other current or planned anti-leukaemia therapies.
- •5. MR4.5 confirmed at screening.
- •6. No signs of extramedullary leukaemia.
- •7. ECOG performance status 0, 1, or 2.
- •8. Calculated (Cockcroft-Gault) or measured glomerular filtration rate greater than or equal to 30 mL/min
- •9. Female patients must have a negative pregnancy test within 24 hours before commencing lenalidomide OR have been amenorrhoeic for at least two years. All patients of reproductive potential must agree to birth control for the duration of the study.
- •10. Life expectancy of more than 12 months in the absence of any intervention.
- •11. Patient has given written, informed consent to participate in the study (which includes consent to obtain samples for the correlative studies).
排除标准
- •1. Patient has received another investigational agent for treatment of CML within last 12 months.
- •2. Atypical BCR-ABL transcript not quantifiable by standard RQ-PCR.
- •3. Another primary malignant disease, except those which do not currently require treatment (adequately treated conditions, such as excised non-melanoma skin cancer or cervical intra-epithelial neoplasia would not be considered exclusion criteria. If in doubt, please refer to the Principal Investigator).
- •4. Another severe and/or life-threatening medical disease.
- •5. Active liver disease (e.g., chronic active hepatitis, cirrhosis).
- •6. History of deep venous thrombosis (in the case of clearly provoked thrombosis more than 2 years prior, please refer to the Principal Investigator).
- •7. Known diagnosis of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- •8. History of non-compliance or inability to grant informed consent.
- •9. Prior allogeneic stem cell transplantation.
研究者
相似试验
进行中（未招募）
不适用
A Phase 1/2 Study of Lenalidomide in combination with Bendamustine (LEBEN) in relapsed and primary refractory Hodgkin Lymphomarelapsed and primary refractory Hodgkin LymphomaMedDRA version: 14.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002810-35-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
进行中（未招募）
不适用
Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) - len-camCLL patientsMedDRA version: 9.1Level: LLTClassification code 10008958Term: Chronic lymphocytic leukaemiaEUCTR2008-001823-71-ITAssociazione Malattie Sangue ONLUS
进行中（未招募）
不适用
Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)EUCTR2008-006919-20-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
进行中（未招募）
1 期
PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA - NDHistological proved diagnosis of B-cell CD20-positive non follicular NHL according to REAL/WHO Classification: a. small lymphocytic lymphoma b. lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, c. nodal marginal zone lymphoma d. splenic marginal zone lymphomae. e. extranodal non-gastric marginal zone lymphomaMedDRA version: 9.1Level: LLTClassification code 10029463MedDRA version: 9.1Level: LLTClassification code 10003911MedDRA version: 9.1Level: LLTClassification code 10041652MedDRA version: 9.1Level: LLTClassification code 10025345EUCTR2008-001591-80-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
进行中（未招募）
不适用
A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosisEUCTR2006-007082-36-GRHellenic Oncology Cooperative Group55